Medical device co Mazor raises double planned sum

Mazor develops the SpineAssist robotic imaging device to facilitate spinal surgical procedures.

Mazor Surgical Technologies Ltd. (TASE:MZOR) raised NIS 48 million in shares and warrants in the public tender of its offering. The tender was held at NIS 9.10 per share, above both the minimum price of NIS 8.50 per share, and the NIS 8.70 set in the institutional tender last week.

Mazor offered the public 5.17 million shares and 3.88 million warrants in units of 100 shares and 75 warrants. The offering of 51,720 units was closed on Thursday. The company received orders for 88,382 units for a total value of NIS 85.1 million.

Thanks to the oversubscription and higher price in the public tender, Mazor was able to raise the amount of planned offering from NIS 25 million to NIS 45 million after the institutional tender, and then to NIS 48 million, altogether.

Mazor develops the SpineAssist robotic imaging device to facilitate spinal surgical procedures.

Israel Healthcare Ventures Ltd. recently sold its 1.5 million shares in Mazor at an average price of NIS 8 per share.

Mazor CEO Ori Hadomi said, "The oversubscription is further evidence of the capital market's esteem for the company, and demands that Mazor continue its rapid growth and sales that began last year."

Mazor's share fell 1% in morning trading today to NIS 8.18, giving a market cap of NIS 119 million.

Published by Globes [online], Israel business news - www.globes-online.com - on October 25, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס